PGEN News and Press, Precigen Inc. From 07/05/22

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire – Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out ...

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit PR Newswire GERMANTOWN, Md. , June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell t...

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference PR Newswire GERMANTOWN, Md. , May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene a...

Precigen press release (NASDAQ:PGEN): Q1 GAAP EPS of -$0.10 beats by $0.03. Revenue of $32M (+30.6% Y/Y) beats by $8.73M. For further details see: Precigen GAAP EPS of -$0.10 beats by $0.03, revenue of $32M beats by $8.73M

Precigen Reports First Quarter 2022 Financial Results and Business Updates PR Newswire – Fast Track designation received for PRGN-3006 UltraCAR-T ® , an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapid...

Protalix BioTherapeutics (PLX) +48% as PRX–102 for Fabry disease equals Sanofi's Fabrazyme in trial. SPI Energy (SPI) +28%. Twitter (TWTR) +20% Trump SPAC Digital World sinks on report two Truth Social executives left, Musk takes Twitter stake. Red Cat Holdings (OTC...

The U.S. Food and Drug Administration granted fast track designation to Precigen's (NASDAQ:PGEN) PRGN-3006 to treat patients with relapsed or refractory acute myeloid leukemia, a cancer of the blood and bone marrow. The company said PRGN-3006 UltraCAR-T is a multigenic autologous chimeri...

Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia PR Newswire – Acute myeloid leukemia (AML) is among the most common types of leukemia in adults – – P...

Gainers: Sera Prognostics (SERA) +10%. Harte-Hanks  (HHS) +7%. Precigen (PGEN) +5%. Greenidge Generation Holdings  (GREE) +5%. IGM Biosciences (IGMS) +5%. Losers: Connect Biopharma Holdings Limited (CNTB) -17%. Arhaus (ARHS) -5%. Fluent (FLNT) -5%. Marinus Pharmaceuticals ...

Precigen press release (NASDAQ:PGEN): Q4 GAAP EPS of -$0.13 beats by $0.01. Revenue of $24.22M (+25.3% Y/Y) beats by $1.98M. Cash, cash equivalents, and short-term and long-term investments totaled $163.7 million as of December 31, 2021 For further details see: Precigen GAAP EPS of -$0....